Malignant Hyperthermia: Management without DANTROLENE | Zendy

Sobia Manzoor | Zendy; Syed Amer Zahoor | Zendy; Jan Mohammad Rather | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Malignant Hyperthermia: Management without DANTROLENE

Author(s) -

Sobia Manzoor,

Syed Amer Zahoor,

Jan Mohammad Rather

Publication year - 2018

Publication title -

j med sci

Language(s) - English

Resource type - Journals

eISSN - 2582-063X

pISSN - 0972-110X

DOI - 10.33883/jms.v21i1.332

Subject(s) - dantrolene , malignant hyperthermia , medicine , anesthesia , hyperthermia , dantrolene sodium , gold standard (test) , surgery , calcium

Malignant Hyperthermia(MH) is a hypermetabolic syndrome which is quite rare in India. Inhalational anesthetics and succinyl choline have been reported as potent triggering agents of MH. Dantrolene remains the gold standard for treating this life-threatening syndrome. We encountered a case of malignant hyperthermia in a 34-year-old male undergoing ventricular septal defect closure under general anesthesia. We successfully managed our patient by timely recognition of this syndrome and by administering prompt, effective symptomatic treatment and without dantrolene which was not available in our hospital. JMS 2018;21(1):40-43

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research